These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19966525)

  • 1. Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay.
    Lee SW; Kim YM; Kim MB; Kim DY; Kim JH; Nam JH; Kim YT
    Tohoku J Exp Med; 2009 Dec; 219(4):277-82. PubMed ID: 19966525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer.
    Lee SW; Kim YM; Kim MB; Kim DY; Kim JH; Nam JH; Kim YT
    Acta Med Okayama; 2012; 66(3):271-7. PubMed ID: 22729108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
    Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
    Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting nedaplatin sensitivity of cervical cancer using the histoculture drug response assay.
    Kato R; Hasegawa K; Achiwa Y; Okamoto H; Torii Y; Oe S; Udagawa Y
    Eur J Gynaecol Oncol; 2011; 32(4):381-6. PubMed ID: 21941957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer.
    Hirano Y; Ushiyama T; Suzuki K; Fujita K
    Urol Res; 1999 Dec; 27(6):483-8. PubMed ID: 10651138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical applications of the histoculture drug response assay.
    Furukawa T; Kubota T; Hoffman RM
    Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues.
    Kodera Y; Ito S; Fujiwara M; Mochizuki Y; Ohashi N; Ito Y; Nakayama G; Koike M; Yamamura Y; Nakao A
    Int J Clin Oncol; 2006 Dec; 11(6):449-53. PubMed ID: 17180513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
    Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
    Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independence of cytotoxic drug sensitivity profiles and receptor subtype of invasive ductal breast carcinoma demonstrated by the histoculture drug response assay (HDRA).
    Kim KY; Chung BW; Yang I; Kim MB; Hoffman RM
    Anticancer Res; 2014 Dec; 34(12):7197-201. PubMed ID: 25503149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay.
    Ariyoshi Y; Shimahara M; Tanigawa N
    Oral Oncol; 2003 Oct; 39(7):701-7. PubMed ID: 12907210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
    Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Reliability of Histoculture Drug Response Assay (HDRA) in Chemosensitivity Tests for Breast Cancer.
    Kang HJ; Ko CD; Yoon HS; Kim MB; Ahn SH
    Cancer Res Treat; 2001 Oct; 33(5):392-7. PubMed ID: 26680813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer].
    Gao GL; Wan HY; Zou XS; Chen WX; Chen YQ; Huang XZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):201-5. PubMed ID: 17537309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Clinical Correlation of the Histoculture Drug Response Assay for Ovarian Cancer.
    Hoffman RM; Jung PS; Kim MB; Nam JH
    Methods Mol Biol; 2018; 1760():73-81. PubMed ID: 29572795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
    Zhang R; Li B; Bai P; Li HJ; Li SM; Wu LY; Li W
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):616-20. PubMed ID: 22325224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
    Qiu F; Zhao X
    J BUON; 2018; 23(1):117-123. PubMed ID: 29552770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Correlation of the Histoculture Drug Response Assay in Gastrointestinal Cancer.
    Hoffman RM
    Methods Mol Biol; 2018; 1760():61-72. PubMed ID: 29572794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemosensitivity test for gastric carcinoma].
    Kubota T
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):495-500. PubMed ID: 9063490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer].
    Tanahashi M; Yamada T; Moriyama S; Suzuki E; Niwa H
    Kyobu Geka; 2008 Jan; 61(1):26-30. PubMed ID: 18186269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer.
    Fujita Y; Hiramatsu M; Kawai M; Nishimura H; Miyamoto A; Tanigawa N
    Oncol Rep; 2009 Feb; 21(2):499-505. PubMed ID: 19148528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.